Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Michael James Overman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5377-135X; OpenAlex author ID A5003827387; NIH RePORTER profile ID 11723500. Sources: ClinicalTrials.gov.

Their work

Papers
35 (first author 1, last author 0)
Trials
2 (principal investigator on 2)
Grants
1
Labs led
0
Collaborators
135
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers, 1 trial · 2017: 5 papers, 1 grant · 2018: 2 papers · 2019: 1 paper, 1 trial · 2020: 7 papers · 2021: 3 papers · 2022: 3 papers · 2023: 1 paper · 2024: 3 papers · 2025: 2 papers · 2026: 2 papers

Papers 35

  1. Phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyag071↗
  2. Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1093/oncolo/oyag423↗
  3. Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/oncolo/oyae182↗
  4. KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-025-01696-0↗
  5. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-024-00505-0↗
  6. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarci… Co-author DOI 10.1136/jitc-2023-006822↗
  7. A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-0499↗
  8. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000005184↗
  9. NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. Co-author DOI 10.1016/j.ctro.2021.12.012↗
  10. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreati… Co-author DOI 10.1016/j.ijrobp.2022.06.089↗
  11. Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer. Co-author DOI 10.6004/jnccn.2022.7018↗
  12. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Co-author DOI 10.1002/cam4.3870↗
  13. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003442↗
  14. Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. Co-author DOI 10.21037/jgo-20-569↗
  15. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2020.2286↗
  16. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.3229↗
  17. Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study. Co-author DOI 10.1002/cam4.3269↗
  18. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Co-author DOI 10.1016/j.pan.2020.01.005↗
  19. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000003763↗
  20. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. Co-author DOI 10.1136/jitc-2020-000587↗
  21. Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-0224↗
  22. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Co-author DOI 10.1073/pnas.1811067116↗
  23. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therap… Co-author DOI 10.1002/cncr.31251↗
  24. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic… Co-author DOI 10.1186/s13045-018-0616-2↗
  25. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2017.2227↗
  26. A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients. Co-author DOI 10.1007/s00520-016-3553-z↗
  27. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. Co-author DOI 10.1007/s11605-016-3265-1↗
  28. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Co-author DOI 10.1093/annonc/mdx004↗
  29. 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-17-0831↗
  30. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cncr.30117↗
  31. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. Co-author DOI 10.1007/s11605-016-3286-9↗
  32. ABO non-O type as a risk factor for thrombosis in patients with pancreatic cancer. Co-author DOI 10.1002/cam4.513↗
  33. Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer? Co-author DOI 10.1007/s13539-014-0145-y↗
  34. The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Co-author DOI 10.1007/s10637-013-9967-2↗
  35. Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.humpath.2013.07.030↗

Trials 2

  1. CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors Principal investigator NCT02757391↗
  2. Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer Principal investigator NCT02600949↗

Grants 1

  1. KRAS Muations in Plasma cfDNA as Predictor to Erolinib Response in Advanced Pancreatic Cancer R21CA202487↗

Closest collaborators

The 25 strongest of 135 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Robert A. Wolff · 27 shared papers, 2013–2026 · strength 2.90
  2. Shubham Pant · 15 shared papers, 2020–2026 · strength 2.08
  3. Matthew H. G. Katz · 21 shared papers, 2013–2026 · strength 2.06
  4. Milind M. Javle · 20 shared papers, 2013–2024 · strength 1.71
  5. Anirban Maitra · 15 shared papers, 2016–2026 · strength 1.59
  6. Ching-Wei David Tzeng · 12 shared papers, 2017–2025 · strength 1.48
  7. Gauri Rajani Varadhachary · 19 shared papers, 2014–2022 · strength 1.47
  8. Eugene Jon Koay · 14 shared papers, 2016–2026 · strength 1.46
  9. David R. Fogelman · 16 shared papers, 2013–2026 · strength 1.33
  10. Brandon George Smaglo · 7 shared papers, 2022–2026 · strength 1.23
  11. Michael P. Kim · 12 shared papers, 2016–2025 · strength 1.22
  12. Naruhiko Ikoma · 9 shared papers, 2020–2026 · strength 1.16
  13. Ethan Bernard Ludmir · 6 shared papers, 2022–2026 · strength 0.93
  14. Jeffrey E. Lee · 11 shared papers, 2016–2023 · strength 0.93
  15. Laura R. Prakash · 10 shared papers, 2016–2023 · strength 0.87
  16. Huamin Wang · 10 shared papers, 2013–2025 · strength 0.87
  17. Rachna T. Shroff · 11 shared papers, 2014–2021 · strength 0.79
  18. Rebecca Anne Snyder · 5 shared papers, 2016–2026 · strength 0.76
  19. Dan Zhao · 4 shared papers, 2024–2026 · strength 0.75
  20. Jason A. Willis · 4 shared papers, 2024–2026 · strength 0.75
  21. Abdelrahman M.G. Yousef · 4 shared papers, 2024–2026 · strength 0.71
  22. Mahmoud Yousef · 4 shared papers, 2024–2026 · strength 0.71
  23. Ryan W. Huey · 3 shared papers, 2025–2026 · strength 0.59
  24. Florencia M. McAllister · 4 shared papers, 2020–2026 · strength 0.54
  25. Saikat Chowdhury · 3 shared papers, 2024–2026 · strength 0.52

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.